Targeted therapeutic palette Abzyme Therapeutics specializes in modular single domain VHH antibody fragments with proprietary discovery platforms and broad program scope across infectious diseases, immuno-oncology, ophthalmology, inflammation, and CNS disorders. This presents cross-disease collaboration opportunities for therapeutic development and diagnostic tools.

Rapid discovery edge Their yeast display self-diversifying libraries and rapid affinity maturation combined with FACS single cell sorting offer a fast track to optimized antibodies with favorable developability profiles, enabling potential partnerships or contract work for accelerated candidate generation and internal capability augmentation.

Strategic partnerships With over sixty proprietary and partnered programs in development, Abzyme appears open to collaboration on both therapeutic and diagnostic applications, creating avenues for co-development, licensing, or research services across biotech and pharma ecosystems.

SBIR leverage Past DoD SBIR Phase II funding signals government-granted validation and potential preference for grantee suppliers; explore opportunities for sponsored research, grant-aligned programs, or funding-aligned collaborations to de-risk early-stage projects.

Targeted outreach Located in the Philadelphia biotech corridor with a small team, Abzyme may value partnerships that provide scale-up, manufacturing support, clinical development input, or contract R&D capacity to complement their modular platform and expand program throughput.